GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (LTS:0OIR) » Definitions » Debt-to-Revenue

Alk-Abello AS (LTS:0OIR) Debt-to-Revenue : 0.10 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Alk-Abello AS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Alk-Abello AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr66 Mil. Alk-Abello AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr444 Mil. Alk-Abello AS's annualized Revenue for the quarter that ended in Sep. 2024 was kr5,252 Mil. Alk-Abello AS's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.10.


Alk-Abello AS Debt-to-Revenue Historical Data

The historical data trend for Alk-Abello AS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Debt-to-Revenue Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.27 0.18 0.15 0.16

Alk-Abello AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.14 0.10 0.09 0.10

Competitive Comparison of Alk-Abello AS's Debt-to-Revenue

For the Biotechnology subindustry, Alk-Abello AS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Debt-to-Revenue falls into.



Alk-Abello AS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Alk-Abello AS's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(326 + 439) / 4824
=0.16

Alk-Abello AS's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(66 + 444) / 5252
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Alk-Abello AS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines